Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors

NCT05662397 is registered in ClinicalTrials.gov with HotSpot Therapeutics, Inc as lead sponsor.

NCT NCT05662397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05662397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
Lead sponsor
HotSpot Therapeutics, Inc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 15, 2023
Completion date
December 31, 2026
Enrollment
77 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

refractory cancer, relapsed cancer, solid tumor, adult